SEC Comment Letter 0000000000-24-006994 to Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899) (PTIX)
Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)
Date: June 18, 2024 · CIK: 0001022899 · Accession: 0000000000-24-006994
AI Filing Summary & Sentiment
File numbers found in text: 333-280244
Letter
United States securities and exchange commission logo June 18, 2024 Garo Armen, Ph.D. Executive Chairman Protagenic Therapeutics, Inc. 149 Fifth Avenue New York, New York 10010 Re:Protagenic Therapeutics, Inc. Registration Statement on Form S-3 Filed June 14, 2024 File No. 333-280244 Dear Garo Armen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Dean M. Colucci, Esq.
Show Raw Text
United States securities and exchange commission logo
June 18, 2024
Garo Armen, Ph.D.
Executive Chairman
Protagenic Therapeutics, Inc.
149 Fifth Avenue
New York, New York 10010
Re:Protagenic Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 14, 2024
File No. 333-280244
Dear Garo Armen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Dean M. Colucci, Esq.